AXQ Capital’s Design Therapeutics DSGN Stock Holding History

AXQ Capital’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,728	Closed	-$110K	–	1069
2025 Q4	$110K	Buy	+11,728	New	+$91.8K	0.02%	640

Other funds holding DSGN

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Point72 Asset Management

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AXQ Capital's DSGN Position: Q1 2026 in Review

AXQ Capital sold out of Design Therapeutics (DSGN) in Q1 2026, closing a stake of 11,728 shares — an estimated $110K sold.

AXQ Capital first reported a position in DSGN in Q4 2025 and held it in 1 quarter. The position peaked at $110K in Q4 2025. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

AXQ Capital reported no remaining Design Therapeutics position as of Q1 2026 after selling out during the quarter.
AXQ Capital sold 11,728 Design Therapeutics shares in Q1 2026, an estimated $110K.
AXQ Capital first reported a position in Design Therapeutics in Q4 2025 and held it in 1 quarter.
AXQ Capital's Design Therapeutics position peaked at $110K in Q4 2025.
125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on AXQ Capital's 13F filing for Q1 2026, filed 13 May 2026.